|
Learn how to use IsoPSA to better determine which patients to defer for biopsy and which to monitor more closely. |
|
Webinar: “Applying IsoPSA's Predictive Power to Guide Patient Monitoring”
|
|
PSA testing alone can leave clinicians without the clarity needed to determine the patient's risk for clinically significant prostate cancer (csPCa). |
|
Join us for a webinar in which Dr. Jason Hafron, Chief Medical Officer of the Michigan Institute of Urology, presents recently published longitudinal data demonstrating how a single result from the IsoPSA Test can help predict a patient's risk for csPCa over 30 months.1 |
|
|
|
|
|
Watch the webinar to hear Dr. Hafron's insight on how the IsoPSA Test can enhance risk stratification, support shared decision-making, and improve patient management. |
|
|
Learn more about the IsoPSA Test
|
|
With greater specificity for clinically significant prostate cancer (csPCa) than total PSA testing and % free PSA, the IsoPSA Test is a blood test that improves risk assessment to better inform biopsy decisions.2
|
|
Backed by an extensive portfolio of publications, the IsoPSA Test is proven by clinical evidence, accepted in clinical guidelines.
|
|
Subscribe to learn more about the test and to receive updates when new CME programs, webinars, and case studies are available.
|
- Abdallah, et al., Urology. 2025 Jan 15:S0090-4295(25)00031-7.
-
Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9-408.e18.
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
